Valvular Heart Disease
|
|
- Alfred Gray
- 6 years ago
- Views:
Transcription
1 Valvular Heart Disease Aortic Stenosis onsultants: Rick A. Nishimura, MD, MA, FAHA o-hair Professor of Medicine Division of ardiovascular Disease Mayo linic atherine M. Otto, MD, FA, FAHA o-hair Professor of Medicine Division of ardiology University of Washington Key Points Evaluation Disease States Guidelineentral.com
2 Table of ontents Key Points Table 1. The Heart Valve Team Evaluation Table 2. nitial Diagnostic Testing Guidelineentral.com Table 3. Frequency of Echocardiograms in Asymptomatic Patients With VHD and Normal LV Function Table 4. Stages of Progression of VHD Table 5. Risk Assessment ombining STS Risk Estimate, Frailty, Major Organ System Dysfunction, and Procedure-Specific mpediments Treatment Table 6. Evaluation and Treatment in Patients With AS Table 7. ndications for AVR in Patients With AS Table 8. hoice of ntervention in Patients With AS Table 9. Stages of Valvular AS Figure 1. ndications for AVR in Patients With AS Recommendation Grading Table Abbreviations
3 Key Points Evaluation ack to Table of ontents ÎÎPatients with VHD may present with a heart murmur, symptoms, or incidental findings of valvular abnormalities on noninvasive testing. ÎÎThe initial evaluation should include a detailed history and physical exam, EG, chest x-ray, and transthoracic echocardiogram. ÎÎDecisions about treatment are based primarily on the presence or absence of symptoms, severity of VHD, and response of the ventricle to pressure or volume overload imposed by VHD. ÎÎVHD requires a multidisciplinary team and approach for its diagnosis and management. ÎÎReasons for valve intervention are to improve symptoms, prolong survival, and reduce the risk of complications. ÎÎAn evaluation of the surgical or interventional risk for each individual patient should be performed if intervention is indicated which includes a standard surgical risk score, along with consideration of comorbidites, frailty, and procedure specfic impediments. ÎÎFollow-up of patients with VHD is important to assess symptom status, provide patient education, and monitor disease severity, typically with periodic echocardiography. Table 2. nitial Diagnostic Testing Recommendations LOE TTE is recommended in the initial evaluation of patients with known or suspected VHD to confirm the diagnosis, establish etiology, determine severity, assess hemodynamic consequences, determine prognosis, and evaluate for timing of intervention. TTE is recommended in patients with known VHD with any change in symptoms or physical examination findings. Periodic monitoring with TTE is recommended in asymptomatic patients with known VHD at intervals depending on valve lesion, severity, ventricular size, and ventricular function. ardiac catheterization for hemodynamic assessment is recommended in symptomatic patients when noninvasive tests are inconclusive or when there is a discrepancy between the findings on noninvasive testing and physical examination regarding severity of the valve lesion. Exercise testing is reasonable in selected patients with asymptomatic severe VHD to confirm the absence of symptoms, or assess the hemodynamic response to exercise, or determine prognosis. a The Heart Valve Team Table 1. The Heart Valve Team Recommendations LOE Patients with severe AS should be evaluated by a multidisciplinary Heart Valve Team when intervention is considered. onsultation with or referral to a Heart Valve enter of Excellence is reasonable when discussing treatment options for asymptomatic patients with severe AS, patients who may benefit from valve repair versus valve replacement, or patients with multiple comorbidities for whom valve intervention is considered. a Table 3. Frequency of Echocardiograms in Asymptomatic Patients With VHD and Normal LV Function Valve Lesion Stage AS a AR MS MR Progressive (stage ) Severe (stage ) Every 3-5 y (mild severity: V max m/s) Every 1-2 y (moderate severity: V max m/s) Every 6-12 mo (V max 4 m/s) Every 3-5 y (mild severity) Every 1-2 y (moderate severity) Every 6-12 mo Dilating LV: more frequently Every 3-5 y (MVA >1.5 cm 2 ) Every 3-5 y (mild severity) Every 1-2 y (moderate severity) Every 1-2 y Every 6-12 mo (MVA cm 2 ) Dilating LV: Once every year more frequently (MVA <1.0 cm 2 ) Patients with mixed valve disease may require serial evaluations at intervals earlier than recommended for single valve lesions. a With normal stroke volume.
4 Evaluation Treatment ack to Table of ontents Table 4. Stages of Progression of VHD Stage Definition Description A At risk Patients with risk factors for development of VHD Progressive Patients with progressive VHD (mild-to-moderate severity and asymptomatic) D Table 5. Risk Assessment ombining STS Risk Estimate, Frailty, Major Organ System Dysfunction, and Procedure- Specific mpediments STS PROM a <4% AND Frailty b Asymptomatic severe Symptomatic severe Low Risk (Must Meet ALL riteria in This olumn) None AND Major organ None system AND compromise not to be improved postoperatively c ntermediate Risk (Any 1 riterion in This olumn) 4%-8% 1 index (mild) 1 organ system Procedurespecific None Possible impediment d impediment procedure-specific Asymptomatic patients who meet the criteria for severe VHD: 1: Asymptomatic patients with severe VHD in whom the left or right ventricle remains compensated 2: Asymptomatic patients with severe VHD, with decompensation of the left or right ventricle Patients who have developed symptoms as a result of VHD High Risk (Any 1 riterion in This olumn) >8% 2 indices (moderate to severe) No more than 2 organ systems Possible procedure-specific impediment Prohibitive Risk (Any 1 riterion in This olumn) Predicted risk with surgery of death or major morbidity (all-cause) >50% at 1 y 3 organ systems Severe procedurespecific impediment a Use of the STS PROM to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are within 1 standard deviation of STS average observed/expected ratio for the procedure in question. b Seven frailty indices: Katz Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting, and urinary continence) and independence in ambulation (no walking aid or assist required or 5-meter walk in <6 s). Other scoring systems can be applied to calculate no, mild-, or moderate-to-severe frailty. c Examples of major organ system compromise: ardiac severe LV systolic or diastolic dysfunction or RV dysfunction, fixed PHTN; KD stage 3 or worse; pulmonary dysfunction with FEV1 <50% or DLO 2 <50% of predicted; NS dysfunction (dementia, Alzheimer s disease, Parkinson s disease, stroke with persistent physical limitation); G dysfunction rohn s disease, ulcerative colitis, nutritional impairment, or serum albumin <3.0; cancer active malignancy; and liver any history of cirrhosis, variceal bleeding, or elevated NR in the absence of VKA therapy. d Examples: tracheostomy present, heavily calcified ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall, or radiation damage. Table 6. Evaluation and Treatment in Patients With AS Recommendations LOE Diagnostic Testing TTE is indicated in patients with signs or symptoms of AS or a bicuspid aortic valve for accurate diagnosis of the cause of AS, hemodynamic severity, LV size and systolic function, and for determining prognosis and timing of valve intervention. Low-dose dobutamine stress testing using echocardiographic or invasive hemodynamic measurements is reasonable in patients with stage D2 AS with all of the following: alcified aortic valve with reduced systolic opening; LVEF <50%; alculated valve area 1.0 cm 2 ; and Aortic velocity <4.0 m/s or Pmean <40 mm Hg. Exercise testing is reasonable to assess physiological changes with exercise and to confirm the absence of symptoms in asymptomatic patients with a calcified aortic valve and aortic velocity 4.0 m/s or Pmean 40 mm Hg (stage ). Exercise testing should NOT be performed in symptomatic patients with AS when the aortic velocity is 4.0 m/s or Pmean is 40 mm Hg (stage D). Medical Therapy Hypertension in patients at risk for developing AS (stage A) and in patients with asymptomatic AS (stages and ) should be treated according to standard GDMT, started at a low dose and gradually titrated upward as needed with frequent clinical monitoring. Vasodilator therapy may be reasonable if used with invasive hemodynamic monitoring in the acute management of patients with severe decompensated AS (stage D) with NYHA class V HF symptoms. Statin therapy is NOT indicated for prevention of hemodynamic progression of AS in patients with mild-to-moderate calcific valve disease (stages -D). a : Harm b : No enefit A
5 Treatment ack to Table of ontents Table 7. ndications for AVR in Patients With AS Recommendations LOE AVR is recommended in symptomatic patients with severe AS (stage D1) with: Decreased systolic opening of a calcified or congenitally stenotic aortic valve; and Aortic velocity 4.0 m/s or Pmean 40 mm Hg; and Symptoms of HF, syncope, exertional dyspnea, angina, or presyncope by history or on exercise testing. AVR is recommended for asymptomatic patients with severe AS (stage 2) and LVEF <50% with decreased systolic opening of a calcified aortic valve with an aortic velocity 4.0 m/s or Pmean 40 mm Hg. AVR is indicated for patients with very severe AS (stage or D) when undergoing cardiac surgery for other indications when there is decreased systolic opening of a calcified aortic valve and aortic velocity 4.0 m/s or Pmean 40 mm Hg. AVR is reasonable for asymptomatic patients with severe AS (stage 1) with: Decreased systolic opening of a calcified valve; Aortic velocity 5.0 m/s or Pmean 60 mm Hg; Low surgical risk. AVR is reasonable in apparently asymptomatic patients with severe AS (stage 1) with: A calcified aortic valve; Aortic velocity m/s or Pmean of mm Hg; An exercise test demonstrating decreased exercise tolerance or a fall in systolic P. AVR is reasonable in symptomatic patients with low-flow/lowgradient severe AS with reduced LVEF (stage D2) with a: alcified aortic valve with reduced systolic opening; Resting valve area 1.0 cm 2 ; Aortic velocity <4 m/s or Pmean<40 mm Hg; LVEF <50%; and Low-dose dobutamine stress study that shows aortic velocity 4 m/s or Pmean 40 mm Hg with valve area 1.0 cm 2 at any dobutamine dose. a a a Table 7. ndications for AVR in Patients With AS (cont'd) Recommendations LOE AVR is reasonable in symptomatic patients with low-flow/ low-gradient severe AS (stage D3) with LVEF 50%, a calcified aortic valve with significantly reduced leaflet motion, and a valve area 1.0 cm 2 only if clinical, hemodynamic, and anatomic data support valve obstruction as the most likely cause of symptoms and data recorded when the patient is normotensive (systolic P <140 mm Hg) indicate: An aortic velocity <4 m/s or Pmean <40 mm Hg; A stroke volume index <35 ml/m 2 ; and An indexed valve area 0.6 cm 2 /m 2. AVR is reasonable for patients with moderate AS (stage ) with an aortic velocity m/s or Pmean mm Hg who are undergoing cardiac surgery for other indications. AVR may be considered for asymptomatic patients with severe AS (stage 1) with aortic velocity 4.0 m/s or Pmean 40 mm Hg if the patient is at low surgical risk and serial testing shows an increase in aortic velocity 0.3 m/s/y. Table 8. hoice of ntervention in Patients With AS Recommendations LOE Surgical AVR is recommended in patients who meet an indication for AVR with low or intermediate surgical risk. For patients in whom TAVR or high-risk surgical AVR is being considered, a Heart Valve Team consisting of an integrated, multidisciplinary group of healthcare professionals with expertise in VHD, cardiac imaging, interventional cardiology, cardiac anesthesia, and cardiac surgery should collaborate to provide optimal patient care. TAVR is recommended in patients who meet an indication for AVR who have a prohibitive risk for surgical AVR and a predicted post-tavr survival >12 months. TAVR is a reasonable alternative to surgical AVR in patients who meet an indication for AVR and who have high surgical risk for surgical AVR. Percutaneous aortic balloon dilation may be considered as a bridge to surgical AVR or TAVR in patients with severe symptomatic AS. TAVR is NOT recommended in patients in whom existing comorbidities would preclude the expected benefit from correction of AS. a a b a b : No enefit A
6 Treatment ack to Table of ontents Table 9. Stages of Valvular AS Stage Definition Valve Anatomy Valve Hemodynamics A At risk of AS icuspid aortic valve (or other congenital valve anomaly) Aortic valve sclerosis Progressive AS Mild-to-moderate leaflet calcification of a bicuspid or trileaflet valve with some reduction in systolic motion or Rheumatic valve changes with commissural fusion : Asymptomatic severe AS 1 Asymptomatic severe AS Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening 2 Asymptomatic severe AS with LV dysfunction D: Symptomatic severe AS D1 Symptomatic severe highgradient AS Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening Hemodynamic onsequences Aortic V max <2 m/s None None Mild AS: Aortic V max m/s or Pmean <20 mm Hg Moderate AS: Aortic V max m/s or Pmean mm Hg Aortic V max 4 m/s or Pmean 40 mm Hg AVA typically 1.0 cm 2 (or AVAi 0.6 cm 2 /m 2 ) Very severe AS: Aortic V max 5 m/s or Pmean 60 mm Hg Aortic V max 4 m/s or Pmean 40 mm Hg AVA typically 1.0 cm 2 (or AVAi 0.6 cm 2 /m 2 ) Aortic V max 4 m/s or Pmean 40 mm Hg AVA typically 1.0 cm 2 (or AVAi 0.6 cm 2 /m 2 ) but may be larger with mixed AS/AR Early LV diastolic dysfunction may be present Normal LVEF LV diastolic dysfunction Mild LV hypertrophy Normal LVEF LVEF <50% LV diastolic dysfunction LV hypertrophy PHTN may be present Symptoms None None: Exercise testing is reasonable to confirm symptom status None Exertional dyspnea or decreased exercise tolerance Exertional angina Exertional syncope or presyncope D2 D3 Symptomatic severe low-flow/lowgradient AS with reduced LVEF Symptomatic severe low-gradient AS with normal LVEF or paradoxical low-flow severe AS Severe leaflet calcification with severely reduced leaflet motion Severe leaflet calcification with severely reduced leaflet motion AVA 1.0 cm 2 with resting aortic V max <4 m/s or Pmean <40 mm Hg DSE shows AVA 1.0 cm 2 with V max 4 m/s at any flow rate AVA 1.0 cm 2 with aortic V max <4 m/s or Pmean <40 mm Hg ndexed AVA 0.6 cm 2 /m 2 and Stroke volume index <35 ml/m 2 Measured when patient is normotensive (systolic P <140 mm Hg) LV diastolic dysfunction LV hypertrophy LVEF <50% ncreased LV relative wall thickness Small LV chamber with low stroke volume Restrictive diastolic filling LVEF 50% HF Angina Syncope or presyncope HF Angina Syncope or presyncope
7 Treatment Symptomatic (stage D1) AVR () Figure 1. ndications for AVR in Patients With AS Severe AS Vmax 4 m/s Pmean 40 mm Hg AVR (a) Abnormal Aortic Valve With Reduced Systolic Opening Asymptomatic (stage D1) LVEF <50% (stage 2) Other cardiac surgery Vmax 5 m/s Pmean 60 mm Hg Low surgical risk Abnormal ETT Vmax 0.3 m/s/y Low surgical risk AVR (b) Vmax m/s Pmean mm Hg Symptomatic LVEF <50% YES DSE with AVA 1 cm 2 and Vmax 4 m/s (stage D2) NO Asymptomatic (stage ) AVA 1 cm 2 and LVEF 50% (stage D3 a ) AS likely cause of symptoms AVR (a) Other cardiac surgery Arrows show decision pathways that result in a recommendation for AVR. Periodic monitoring is indicated for all patients in whom AVR is not yet indicated, including those with asymptomatic AS (stage D or ) and those with low-gradient AS (stage D2 or D3) who do not meet the criteria for intervention. a AVR should be considered with stage D3 AS only if valve obstruction is the most likely cause of symptoms, stroke volume index is <35 ml/m 2, indexed AVA is 0.6 cm 2 /m 2, and data are recorded when the patient is normotensive (systolic P <140 mm Hg). A recommendation with Level of Evidence or does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even when randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. a Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior M, history of HF, and prior aspirin use. b For comparative effectiveness recommendations (lass and a; Level of Evidence A and only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated. omparative effectiveness phrases b : treatment/strategy A is recommended/indicated in preference to treatment treatment A should be chosen over treatment treatment/strategy A is probably recommended/indicated in preference to treatment it is reasonable to choose treatment A over treatment Suggested phrases for writing recommendations: should is recommended is indicated is /beneficial is reasonable can be /beneficial is probably recommended or indicated may/might be considered may/might be reasonable usefulness/effectiveness is unknown/unclear/uncertain or not well established : No enefit is not recommended is not indicated should not be performed/ administered/other is not useful/beneficial/ effective : Harm potentially harmful causes harm associated with excess morbidity/mortality should not be performed/ administered/other Estimate of ertainty (precision) of Treatment Effect meta-analyses meta-analyses LEVEL Recommendation that Limited populations evaluated a procedure or treatment is Data derived from a single randomized trial or Evidence from single nonrandomized studies randomized trial or nonrandomized studies LEVEL Recommendation that Very limited populations procedure or treatment is evaluated a Only consensus opinion of experts, case studies, or Only expert opinion, case standards of care studies, or standard of care trials or meta-analyses Recommendation in favor of treatment or procedure being Some conflicting evidence from single randomized trial or nonrandomized studies Recommendation in favor of treatment or procedure being Only diverging expert opinion, case studies, or standard of care Recommendation's usefulness/efficacy less well established Only diverging expert opinion, case studies, or standard of care Recommendation that procedure or treatment is not and may be harmful Only expert opinion, case studies, or standard of care Recommendation's usefulness/efficacy less well established Greater conflicting evidence from single randomized trial or nonrandomized studies Recommendation that procedure or treatment is not and may be harmful Evidence from single randomized trial or nonrandomized studies ack to Table of ontents Estimate of ertainty (Precision) of Treatment Effect LEVEL A Multiple populations evaluated a Data derived from multiple randomized clinical trials or Recommendation that procedure or treatment is Sufficient evidence from multiple randomized trials or Recommendation in favor of treatment or procedure being Some conflicting evidence from multiple randomized Recommendation's usefulness/efficacy less well established Greater conflicting evidence from multiple randomized trails or meta-analyses Recommendation that procedure or treatment is not and may be harmful Sufficient evidence from multiple randomized trials of meta-analyses : Harm Excess ost w/o enefit or Harmful Harmful to Patients LASS enefit >>> Risk Procedure/Treatment SHOULD be performed/ administered LASS a enefit >> Risk Additional studies with focused objectives needed T S REASONALE to perform procedure/ administer treatment LASS b enefit Risk Additional studies with broad objectives needed; additional registry data would be helpful Procedure/Treatment MAY E ONSDERED : No benefit Not Helpful No Proven enefit Procedure/ Test Treatment LASS No enefit or LASS Harm Size of Treatment Effect
8 ack to Table of ontents Abbreviations 2-D, 2-dimensional, AVAi, aortic valve area indexed to body surface area; AVR, aortic valve replacement; P, blood pressure; KD, chronic kidney disease; NS, central nervous system;, lass of Recommendation; VA, cardiovascular accident (stroke); DLO 2, carbon dioxide diffusing capacity of the lungs; DSE, dobutamine stress echocardiography; EG, electrocardiogram, FEV1, forced expiratory volume in 1 second; G, gastrointestinal; GDMT, guideline-directed medical therapy; HF, heart failure; NR, international normalized ratio; LOE, Level of Evidence; LV, left ventricular; LVEF, left ventricular ejection fraction; m/s, meters per second; NYHA, New York Heart Association; ΔP, pressure gradient; PHTN, pulmonary hypertension, PROM, predicted risk of mortality; RT, randomized controlled trial; RV, right ventricular; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement; TTE, transthoracic echocardiography/echocardiogram; VKA, vitamin K antagonist; V max, maximal velocity; y, year This resource is provided compliments of Edwards Lifesciences LL. t is intended for reference use only and healthcare providers must make clinical judgments based on their independent assessment of each patient. Edwards Lifesciences LL was not involved in the development of the underlying guidelines on which this publication is based. AR12009 Source Nishimura RA, Otto M, onow RO, arabello A, Erwin JP, Guyton RA, O Gara PT, Ruiz E, Skubas NJ, Sorajja P, Sundt TM, Thomas JD AHA/A guideline for the management of patients with valvular heart disease: a report of the American ollege of ardiology/american Heart Association Task Force on Practice Guidelines. J Am oll ardiol 2014;63:e opublished in irculation 2014;129:e521-e643. Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. t focuses on the needs of primary care practice, but also is applicable to providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician after consideration of each individual patient situation. Neither G, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. AVHDAS14081c 106 ommerce Street, Suite 105 Lake Mary, FL TEL: FAX: For additional copies: info@guidelineentral.com opyright 2014 All rights reserved
A Health Care Professional s Guide Aortic Stenosis in Seniors
A Health Care Professional s Guide Aortic Stenosis in Seniors With highlights from the 2014 ACC/AHA practice guidelines for valve disease Aortic stenosis (AS) is primarily caused by calcification of the
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationAortic Stenosis: Spectrum of Disease, Low Flow/Low Gradient and Variants
Aortic Stenosis: Spectrum of Disease, Low Flow/Low Gradient and Variants Martin G. Keane, MD, FASE Professor of Medicine Lewis Katz School of Medicine at Temple University Basic root structure Parasternal
More informationAortic Valve Stenosis and TAVR: Putting it all together.
Aortic Valve Stenosis and TAVR: Putting it all together. Maria L. Held, MSN CNS Valve Clinic Coordinator at The Cleveland Clinic Alliance of Cardiovascular Professionals April 14 th, 2018 Brief Anatomy
More informationLow Gradient Severe? AS
Low Gradient Severe? AS Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Institut Universitaire de Cardiologie et de Pneumologie de Québec / Québec Heart
More informationAortic Valvular Stenosis
Aortic Valvular Stenosis How to Assess the Four Variables for Management Low Flow / Low Gradient / Normal EF / Low EF Patrick T. O Gara, MD, MACC Brigham and Women s Hospital Harvard Medical School No
More informationRISK PREDICTION IN TAVR. Beyond STS PROM and the Eyeball Assessment
RISK PREDICTION IN TAVR Beyond STS PROM and the Eyeball Assessment SAVR VS TAVR BIOPROSHETIC OPEN SURGICAL VALVE (SAVR) BIOPROSTHETIC TRANSCATHETER VALVE (TAVR) This Photo by Unknown Author is licensed
More informationAortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology
Aortic Stenosis: UPDATE 2010 Anjan Sinha, MD Krannert Institute of Cardiology None Disclosures 67-Year-Old Male Dyspnea and angina Class III heart failure No PND or orthopnea 3/6 late peak SEM Diminished
More informationLearn and LiveSM. ACC/AHA Pocket Guideline. Based on the ACC/AHA 2006 Guideline Revision. Management of Patients With. Valvular Heart Disease
Learn and LiveSM ACC/AHA Pocket Guideline Based on the ACC/AHA 2006 Guideline Revision Management of Patients With Valvular Heart Disease June 2006 Special thanks to Distributed through support from Medtronic
More informationOntario Transcatheter Aortic Valve Implantation (TAVI) Patient Eligibility Criteria Guidelines & Facility Quality Criteria
Ontario Transcatheter Aortic Valve Implantation (TAVI) Patient Eligibility Criteria Guidelines & Facility Quality Criteria August 2018 CorHealth Ontario 1 Table of Contents 3 About CorHealth Ontario 3
More informationAortic stenosis in octogenarians and comorbidities. Constantinos Evdoridis, MD Elpis General Hospital, Athens
Aortic stenosis in octogenarians and comorbidities Constantinos Evdoridis, MD Elpis General Hospital, Athens Decision to operate according to age range European Heart Journal (2005) 26, 2714 2720 Fitness
More informationTAVR: Echo Measurements Pre, Post And Intra Procedure
2017 ASE Florida, Orlando, FL October 10, 2017 8:00 8:25 AM 25 min TAVR: Echo Measurements Pre, Post And Intra Procedure Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationNothing to Disclose. Questions. Disclosure Asymptomatic Severe Aortic Stenosis: (When) Should One Intervene? Paul Wood at the Nathanson Lecture, 1958
Disclosure Asymptomatic Severe Aortic Stenosis: (When) Should One Intervene? Nothing to Disclose Gabriel Gregoratos, MD, FACC, FAHA Questions Can one improve globally on the asymptomatic state? and if
More informationUnderstanding the guidelines for Interventions in MR. Ali AlMasood
Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe
More information2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease
2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease Patrick T. O Gara, MD BWH Heart and Vascular Center Professor of Medicine, Harvard Medical School Disclosures NHLBI CTSN Co-chair
More informationRisk assessment. Heart Team Evaluation
Chapter 8: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines. Iliana S. Hurtado Rendón, MD, Peter Bittenbender, MD, Justin M. Dunn, MD, MPH, Michael S. Firstenberg, MD Akron
More informationValvular Guidelines: The Past, the Present, the Future
Valvular Guidelines: The Past, the Present, the Future Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief,
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationWelcome 17 Michigan TAVR Participating Hospitals!
Welcome 17 Michigan TAVR Participating Hospitals! 1 MICHIGAN TAVR BRIEF OVERVIEW HOW AND WHY PRE-TAVR IMAGING EVALUATION AND THE TVT Michael Grossman, MD Co-Director, BMC2 Coordinating Center Why Michigan
More informationThe prevalence of calcific aortic valve disease approaches. Compendium. Current Management of Calcific Aortic Stenosis
Compendium Circulation Research Compendium on Aortic Valve Disease: Introduction to the Compendium Introduction to Aortic Stenosis Hemodynamic and Cellular Response Feedback in Calcific Aortic Valve Disease
More informationHypertension in Aortic Valve Disease
Hypertension in Aortic Valve Disease Hanna M. Nosseir MRCP, FRCP Head of Cardiology department Galaa Military Medical Complex Aortic stenosis: Introduction Arterial hypertension and aortic stenosis are
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More information2/4/2019. Nursing Perspective of TAVR. Disclosure. Learning Outcomes
Nursing Perspective of TAVR Tara Whitmire, DNP, APRN-NP, NP-C, CHFN Nebraska Methodist Hospital Cardiothoracic Surgery Nurse Practitioner Danelle Homeyer, RN Methodist Physicians Clinic Director, Structural
More informationStress Testing in Valvular Disease
2017 ASE Florida Orlando, FL October 10, 2017 2:40 2:50 PM 10 min Grand Harbor Ballroom South Stress Testing in Valvular Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationMixed aortic valve disease
Mixed aortic valve disease IOANNIS NTALAS MD, PhD Cardiologist, Clinical Fellow in Cardiovascular Imaging & Non-Invasive Cardiology, St Thomas Hospital School of Biomedical Engineering & Imaging Sciences
More informationUsually we DON T need to go beyond the gradient
Aortic Stenosis Going Beyond the Gradient James D. Thomas, MD, FACC, FASE Director, Center for Heart Valve Disease Bluhm Cardiovascular Institute Professor of Medicine, Feinberg School of Medicine, Northwestern
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationSpotlight on Valvular Heart Disease Guidelines
Spotlight on Valvular Heart Disease Guidelines Aortic Valve Disease Raphael Rosenhek Department of Cardiology Medical University of Vienna Palermo, April 26 th 2018 1998 2002 2006 2007 2008 2012 2014 2017
More informationSténose aortique à Bas Débit et Bas Gradient
3.6 m/s Sténose aortique à Bas Débit et Bas Gradient Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Doctorate Honoris Causa, Université de Liège Institut
More informationAortic Regurgitation & Aorta Evaluation
VALVULAR HEART DISEASE Regurgitation Valvular Lessions 2017 Aortic Regurgitation & Aorta Evaluation Jorge Eduardo Cossío-Aranda MD, FACC Chairman of Outpatient Care Department Instituto Nacional de Cardiología
More informationAssessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University
Assessment and Preparation of Patients with TAVI Rob Tanzola Associate Professor, Queen s University My patient has aortic stenosis and needs non-cardiac surgery Should (s)he get a TAVI? Rob Tanzola Associate
More informationSection 1: Initial Evaluation for Valvular Heart Disease Table 1: Initial Evaluation of an Asymptomatic Patient
Section 1: Initial Evaluation for Valvular Heart Disease Table 1: Initial Evaluation of an Asymptomatic Patient Indication 1. Unexplained murmur or abnormal heart sounds 2. Reasonable suspicion of valvular
More informationComprehensive Echo Assessment of Aortic Stenosis
Comprehensive Echo Assessment of Aortic Stenosis Smonporn Boonyaratavej, MD, MSc King Chulalongkorn Memorial Hospital Bangkok, Thailand Management of Valvular AS Medical and interventional approaches to
More informationGuideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Learn and Live SM. ACCF/AHA Pocket Guideline
Learn and Live SM ACCF/AHA Pocket Guideline Based on the 2010 ACCF/AHA Guideline Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults November 2010 Guideline for Assessment of Cardiovascular
More informationLow Gradient AS: Multi-Imaging Modalities
Low Gradient AS: Multi-Imaging Modalities Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Institut Universitaire de Cardiologie et de Pneumologie de
More informationAortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC No Financial Disclosures Aortic Stenosis AS is an insidious disease with a long latency period followed by
More informationMeasuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France
Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Faculty disclosure Bernard Iung I disclose the following financial relationships: Consultant
More informationMenachem M. Weiner Assistant Professor of Anesthesiology Icahn School of Medicine at Mount Sinai
Menachem M. Weiner Assistant Professor of Anesthesiology Icahn School of Medicine at Mount Sinai Anesthetic care and considerations Intraoperative events TEE Perioperative complications Most common valvular
More informationCardiac MRI in ACHD What We. ACHD Patients
Cardiac MRI in ACHD What We Have Learned to Apply to ACHD Patients Faris Al Mousily, MBChB, FAAC, FACC Consultant, Pediatric Cardiology, KFSH&RC/Jeddah Adjunct Faculty, Division of Pediatric Cardiology
More informationBy the end of this session, the student should be able to:
Valvular Heart disease HVD By Dr. Ashraf Abdelfatah Deyab VHD- Objectives By the end of this session, the student should be able to: Define and classify valvular heart disease. Enlist the causes of acquired
More informationWorldwide rheumatic fever is the most common cause of valve disease. In industrialized areas, valvular disease of old age predominates
Michael Sumners DO Epidemiology Worldwide rheumatic fever is the most common cause of valve disease In industrialized areas, valvular disease of old age predominates Calcific aortic stenosis Functional
More information2019 Qualified Clinical Data Registry (QCDR) Performance Measures
2019 Qualified Clinical Data Registry (QCDR) Performance Measures Description: This document contains the 18 performance measures approved by CMS for inclusion in the 2019 Qualified Clinical Data Registry
More informationValve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.
Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Professor, Thoracic and Cardiovascular Surgery University of Florida klodell@surgery.ufl.edu Disclosures
More informationAS with reduced LV ejection fraction: Contractile reserve should be systematically assessed: PRO
AS with reduced LV ejection fraction: Contractile reserve should be systematically assessed: PRO Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Potential conflicts of interest
More informationCardiac Valve/Structural Therapies
Property of Dr. Chad Rammohan Cardiac Valve/Structural Therapies Chad Rammohan, MD FACC Medical Director, El Camino Hospital Cardiac Catheterization Lab Director, Interventional and Structural Cardiology,
More informationMy Heart Will Go on: Disclosures 3/2/2018
My Heart Will Go on: ANTICOAGULATION NO LONGER STOPS AT VALVULAR HEART DISEASE Nicholas Boemio, PharmD PGY-1 Pharmacy Practice Resident VA Connecticut Healthcare System Kim L. Daley, PharmD, BCGP, CDP
More informationPreprocedural evaluation for TAVR
KEBE 30/05/15 Preprocedural evaluation for TAVR Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece Clinical Pathway: Developing Peri- Procedural Protocols
More informationPolicy Specific Section: March 30, 2012 March 7, 2013
Medical Policy Transcatheter Aortic Valve Replacement for Aortic Stenosis Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date:
More informationEjection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.
Valvular Heart Disease Etiology General Principles Cellular and molecular mechanism of valve damage Structural pathology Functional pathology - stenosis/regurgitation Loading conditions - pressure/volume
More information22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.
Oxford City Transcatheter aortic valve replacement 2017 guidelines Monday 19 th June Jim Newton Oxford Oxford University Hospitals NHS FT How familiar are you with TAVR? 1. First time I have heard about
More informationTAVR : Caring for your patients before and after TAVR
TAVR : Caring for your patients before and after TAVR Zubair Ahmed MD FSCAI Interventional Cardiologist Washington Regional Medical Center / Walker Heart Institute What is Aortic Valve Stenosis? AVA ~4
More informationLow Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor
Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University
More informationValvular Heart Disease
Valvular Heart Disease B K Singh, MD, FACC Disclosures: None 1 CARDIAC CYCLE S2 S2=A2P2 S1=M1T1 S4 S1 S3 2 JVP Carotid S1 Slitting of S2 S3 S4 Ejection click Opening snap Dynamic Auscultation What is the
More informationIndicator Mild Moderate Severe
Indicator Mild Moderate Severe Jet velocity (m/s) 2.0-2.9 3.0-3.9 4.0 Mean gradient (mmhg) < 20 20-39 40 Valve area (cm 2 ) 1.0 Valve area index (cm 2 /m 2 ) 0.6 1 Abnormal AV with Reduced Systolic Opening
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationHOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?
HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? John D. Carroll, MD Professor, Director of Interventional Cardiology and Co-Medical Director of the Cardiac and Vascular Center, University of Colorado
More information«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer
«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Université LAVAL
More informationEjection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.
Valvular Heart Disease General Principles Etiology Cellular and molecular mechanism of valve damage Structural pathology Functional pathology - stenosis/regurgitation Loading conditions - pressure/volume
More informationHISTORY. Question: What category of heart disease is suggested by the fact that a murmur was heard at birth?
HISTORY 23-year-old man. CHIEF COMPLAINT: Decreasing exercise tolerance of several years duration. PRESENT ILLNESS: The patient is the product of an uncomplicated term pregnancy. A heart murmur was discovered
More informationDisclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech
Disclosures ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech Speaker s fee Edwards Lifesciences Sanofi-Aventis Decision Making in Patients with Multivalvular
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationThe production of murmurs is due to 3 main factors:
Heart murmurs The production of murmurs is due to 3 main factors: high blood flow rate through normal or abnormal orifices forward flow through a narrowed or irregular orifice into a dilated vessel or
More informationPrimary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017
Disclosures: GE stock, Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Athena Poppas, MD FACC Past ACC Scientific Sessions Chair, ACC Board
More informationECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction
Role of Stress Echo in Valvular Heart Disease ECHO HAWAII January 15 19, 2018 Kenya Kusunose, MD, PhD, FASE Tokushima University Hospital Japan Not only ischemia! Cardiomyopathy Prosthetic Valve Diastolic
More informationMy Heart Will Go on: ANTICOAGULATION NO LONGER STOPS AT VALVULAR HEART DISEASE
Disclosures My Heart Will Go on: ANTICOAGULATION NO LONGER STOPS AT VALVULAR HEART DISEASE Nicholas Boemio, PharmD- No potential or actual conflicts of interest to disclose Kim L. Daley, PharmD, BCGP,
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationHow to Assess and Treat Obstructive Lesions
How to Assess and Treat Obstructive Lesions Erwin Oechslin, MD, FESC, FRCPC, Director, Congenital Cardiac Centre for Adults Peter Munk Cardiac Centre University Health Network/Toronto General Hospital
More informationStage of Valvular AS. Outline 10/14/16. Low-flow and Other Challenges to the Assessment of Aortic Stenosis. Severe AS
Low-flow and Other Challenges to the Assessment of Aortic Stenosis Nithima Ratanasit, MD, FACC, FASE Siriraj Hospital, Mahidol University Bangkok, Thailand Outline Types of low-flow aortic stenosis Assessment
More informationAortic Stenosis and Perioperative Risk With Non-cardiac Surgery
Aortic Stenosis and Perioperative Risk With Non-cardiac Surgery Aortic stenosis (AS) is characterized as a high-risk index for cardiac complications during non-cardiac surgery. A critical analysis of old
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationNatural History and Echo Evaluation of Aortic Stenosis
Natural History and Echo Evaluation of Aortic Stenosis Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM AORTIC STENOSIS First valvular disease
More informationESC/EACTS Guidelines for the Management of Valvular Heart Disease
ES/EATS Guidelines for the Management of Valvular Heart Disease European Journal of ardio-thoracic Surgery 2012 - Why do we need new guidelines on the management of valvular disease? New evidence has been
More informationAortic Valve Replacement Improves Outcome in Patients with Preserved Ejection Fraction: PRO!
ESC 2011, Paris Controversies in Low-Flow, Low-Gradient Aortic Stenosis Aortic Valve Replacement Improves Outcome in Patients with Preserved Ejection Fraction: PRO! Philippe Pibarot, DVM, PhD, FACC, FAHA,
More informationThe Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD
The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New
More informationManaging the Low Output Low Gradient Aortic Stenosis Patient
Managing the Low Output Low Gradient Aortic Stenosis Patient R A Nishimura MD Judd and Mary Leighton Professor of CV Mayo Clinic No disclosures Valvular Stenosis Severity of Aortic Stenosis Mean gradient
More informationSONOGRAPHER & NURSE LED VALVE CLINICS
SONOGRAPHER & NURSE LED VALVE CLINICS Frequency of visits and alerts AORTIC STENOSIS V max > 4.0 m/s or EOA < 1.0 cm 2 V max 3.5 4.0 m/s + Ca+ V max 3.0 4.0 m/s or EOA 1.0-1.5 cm 2 V max 2.5 3.0 m/s every
More informationValvular Heart Disease: Assessment and Timing of Intervention. Graham Cole Consultant Cardiologist Imperial College Healthcare NHS Trust
Valvular Heart Disease: Assessment and Timing of Intervention Graham Cole Consultant Cardiologist Imperial College Healthcare NHS Trust Disclosures: Speaker fee: Bayer Acknowledgements: Matt Shun-Shin
More informationDegenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention
Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention John N. Hamaty D.O. FACC, FACOI November 17 th 2017 I have no financial disclosures Primary Mitral
More informationManagement of significant asymptomatic aortic stenosis. Alec Vahanian Bichat Hospital University Paris VII Paris, France
Management of significant asymptomatic aortic stenosis. Alec Vahanian Bichat Hospital University Paris VII Paris, France Background Aortic stenosis (AS) is the most frequent valve disease among referred
More informationHeart Team For TAVI Who and How?
2 nd TAVI Summit 2012, Seoul Corea Heart Team For TAVI Who and How? Alain Cribier, MD, Charles Nicolle Hospital University of Rouen, France Disclosure Edwards Lifesciences Consultant Training / proctoring
More informationManagement of Aortic Valve Disease: Review Questions
S e l f - A s s e s s m e n t i n C a r d i o l o g y Management of Aortic Valve Disease: Review Questions Josh Leitner, MD Wen-Chih Wu, MD QUESTIONS Choose the single best answer for each question. Questions
More informationAortic stenosis aetiology: morphology of calcific AS,
How to improve patient selection in aortic stenosis? Fausto J. Pinto, FESC Aortic stenosis aetiology: morphology of calcific AS, bicuspid valve, and rheumatic AS (Adapted from C. Otto, Principles of
More informationValvular heart disease (VHD) is present in 2.5% of the
2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations Richard Matiasz, MD; Vera H. Rigolin, MD Valvular heart disease (VHD) is present in 2.5% of the
More informationNY STATE NPA 33 rd Annual Conference TAVR & Structural Heart Update
NY STATE NPA 33 rd Annual Conference TAVR & Structural Heart Update October 21, 2017 Rose Hansen DNP Structural Heart Coordinator Gates Vascular Institute, Buffalo NY TAVR Update: Objectives 1. Understand
More informationFocused. se with 2008 F. lar Heart Diseas. date. ents With Valvul. Upd. gement of Patie. lines for Manag. HA 2006 Guidel ACC/AH. Fig.
ACC/AH HA 2006 Guidel nic severe AI (Fig. 4). ned by age, ay also be helpful nd echo. For AI, ollow up may be or MRI rather than mension; SD, end lines for Manag gement of Patie Upd ents With Valvul date
More informationThe production of murmurs is due to 3 main factors:
Heart murmurs The production of murmurs is due to 3 main factors: high blood flow rate through normal or abnormal orifices forward flow through a narrowed or irregular orifice into a dilated vessel or
More informationAsymptomatic Valvular Disease:
Asymptomatic Valvular Disease: Can Echocardiography Help You Decide When to Intervene? Neil J. Weissman, MD MedStar Health Research Inst at MedStar Washington Hospital Center & Professor of Medicine Georgetown
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationWhich one of the following echocardiographic profiles most strongly indicates the need for aortic valve replacement? FS [
Question 46 A 45-year-old asymptomatic man returns for follow-up. He was diagnosed 10 years ago with aortic regurgitation due to a congentia lbicuspid aortic valve, He has never had endocarditis Which
More informationClinical Outcome in Patients with Aortic Stenosis
Clinical Outcome in Patients with Aortic Stenosis Is the Prognosis Worse in Patients with Low-Gradient Severe Aortic Stenosis? Yoel Angel BSc, Shemy Carasso MD, Diab Mutlak MD, Jonathan Lessick MD Dsc,
More informationDobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies
Dobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies Mitral Regurgitation The New ASE Guidelines: Role of 2D/3D and CMR William A. Zoghbi MD, FASE, MACC Professor and
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationChapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine
Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the
More informationBogdan A. Popescu. University of Medicine and Pharmacy Bucharest, Romania. EAE Course, Bucharest, April 2010
Bogdan A. Popescu University of Medicine and Pharmacy Bucharest, Romania EAE Course, Bucharest, April 2010 This is how it started Mitral stenosis at a glance 2D echo narrow diastolic opening of MV leaflets
More informationOn Referral to our Unit
Case Presentation By Samah Ibrahim Abdel Meguid Idris, MD Internal Medicine & Nephrology Consultant Head of Hemodialysis Unit Ahmed Maher Hospital, Alexandria Patient Data MEA 27-year-old male patient
More informationReverse left atrium and left ventricle remodeling after aortic valve interventions
Reverse left atrium and left ventricle remodeling after aortic valve interventions Alexandra Gonçalves, Cristina Gavina, Carlos Almeria, Pedro Marcos-Alberca, Gisela Feltes, Rosanna Hernández-Antolín,
More informationLow Gradient AS Normal LVEF
Low Gradient AS Normal LVEF Shahbudin H. Rahimtoola MB, FRCP, MACP, MACC, FESC, D.Sc.(Hon) Distinguished Professor University of Southern California Griffith Professor of Cardiology Professor of Medicine
More informationClinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!
Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Abha'Khandelwal,'MD,'MS' 'Stanford'University'School'of'Medicine'
More informationTAVR Patient Screening & Identification Guide
TAVR Patient Screening & Identification Guide Severe Aortic Stenosis is Life Threatening Patients may live with aortic stenosis for many years during a latent, asymptomatic period, even before symptoms
More information